Prime Medicine (PRME) Interest & Investment Income (2023 - 2026)
Prime Medicine posted quarterly Interest & Investment Income of $1.0 million for Q1 2026, down 13.62% year-on-year from $1.2 million in Q1 2025, and down 5.72% on a QoQ basis from $1.1 million in Q4 2025.
Prime Medicine (PRME) has 4 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 13.62% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 0.99% YoY), and the FY2025 full-year result was $4.1 million, up 17.8% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.0 million, down from $1.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.5 million in Q4 2024 and bottomed at $410000.0 in Q3 2023.
- The 4-year median for Interest & Investment Income is $720000.0 (2024), against an average of $852333.3.
- The widest annual swing landed in 2024, when Interest & Investment Income surged 213.24%; it then declined 29.58% in 2025.
- A 4-year view of Interest & Investment Income shows it stood at $491000.0 in 2023, then soared by 213.24% to $1.5 million in 2024, then slipped by 29.58% to $1.1 million in 2025, then retreated by 5.72% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 743,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 697,000.00 |
| Jun 30, 2024 | 611,000.00 |
| Mar 31, 2024 | 676,000.00 |
| Dec 31, 2023 | 491,000.00 |
| Sep 30, 2023 | 410,000.00 |
| Jun 30, 2023 | 635,000.00 |